| Literature DB >> 34898791 |
Dogan Gursoy1,2, Yuksel Ekinci3, Ali Selcuk Can3, Jessica C Murray1.
Abstract
This research examines the effectiveness of message framing, message appeal and information content in changing respondents' COVID-19 vaccination intentions through influencing their vaccine risk perceptions. Furthermore, the moderating effect of travel desire on the relationship between vaccine risk perceptions and changing vaccination intentions is examined. In doing so, two rounds of data that were collected from the same respondents. The first survey recorded respondents' vaccination intentions, travel desire and socio demographics. A follow up survey tested cause-and-effect relationships on the proposed relationships using a 2 (message frame: gain, loss) x 2 (message appeal: rational, emotional) ×2 (information content: subjective, objective) between-subjects online experimental design. Findings suggest that loss-framed messages are more effective than gain-framed and emotional-rational messages in reducing risk perceptions and, thus, changing vaccination intentions. Travel desire is found to moderate the effect of vaccine risk perception on vaccination intentions by weakening the negative effect of vaccine risk perception on vaccination intention. Findings show the importance of travel desire along with message framing and message appeal on changing individuals' COVID-19 vaccination intentions in public health communications.Entities:
Keywords: COVID-19 vaccination intention; Message appeal; Message frame; Perceived vaccine risk; Travel desire
Year: 2021 PMID: 34898791 PMCID: PMC8651509 DOI: 10.1016/j.tourman.2021.104468
Source DB: PubMed Journal: Tour Manag ISSN: 0261-5177
Fig. 1The research model.
Demographic information of participants.
| Demographic | Study 1 (n = 1021) | Study 2 (n = 266) | |
|---|---|---|---|
| Gender | Male | 48.7 | 40.2 |
| Female | 49.7 | 59.4 | |
| Other | 1.7 | .4 | |
| Marital status | Cohabiting | 10.2 | 10.9 |
| Divorced/Separated/Widowed | 7.6 | 10.5 | |
| Married | 37.6 | 42.5 | |
| Single | 44.6 | 36.1 | |
| Age | 18–25 | 22.5 | 12.0 |
| 26–35 | 32.8 | 32.3 | |
| 36–45 | 22.7 | 30.8 | |
| 46–55 | 12.3 | 15.4 | |
| Over 55 | 9.6 | 9.4 | |
| Education | High school graduate (high school diploma or equivalent including GED) or less | 12.3 | 15.0 |
| Some college but no degree | 20.1 | 26.7 | |
| Associate degree in college (2-year) | 10.3 | 10.5 | |
| Bachelor's degree in college (4-year) | 36.8 | 33.1 | |
| Master's/Doctoral/Professional (JD, MD) degree | 20.5 | 14.7 | |
| Annual income | Unemployed | 11.9 | 11.7 |
| Less than $ 19,999 | 18.8 | 19.9 | |
| $20,000–39,999 | 20.5 | 20.3 | |
| $40,000–59,999 | 16.4 | 18.0 | |
| $60,000–79,999 | 13.5 | 9.4 | |
| $80,000 or more | 19.0 | 20.7 | |
| Occupation | Construction, extraction, maintenance, farming, fishing, and forestry | 3.5 | 3.4 |
| Frontline essential workers | 2.4 | 3.4 | |
| Government | 4.7 | 1.9 | |
| Healthcare professional | 5.8 | 3.0 | |
| Management, professional, and related | 26.2 | 23.7 | |
| Production, transportation, and material moving | 4.0 | 3.8 | |
| Retired | 2.8 | 3.0 | |
| Sales and office | 14.0 | 19.9 | |
| Service | 13.4 | 13.5 | |
| Unemployed | 23.0 | 24.4 | |
Results for post-hoc (Tukey) tests for perceived vaccine risk.
| Mean | Mean Difference | ||
|---|---|---|---|
| Gain Subjective | 3.71 | ||
| Gain Objective | 3.37 | .34 | .19 |
| Loss Subjective | 3.23 | .48 | .03* |
| Loss Objective | 3.10 | .61 | .00* |
| Rational Subjective | 3.52 | ||
| Rational Objective | 3.50 | .02 | .99 |
| Emotional Subjective | 3.43 | .09 | .95 |
| Emotional Objective | 2.99 | .53 | .01* |
p < .05.
Model coefficients for the conditional process model.
| Antecedents | Outcomes | |||||||
|---|---|---|---|---|---|---|---|---|
| Perceived vaccine risk (M) | Changes (ΔVI) in COVID-19 vaccination intention (Y) | |||||||
| Coeff. | S.E. | p | Coeff. | S.E. | p | |||
| Model 1: Message frame (gain/loss) R2 = .39, F(4,261) = 42.490, p < .001 | ||||||||
| Gain vs loss framed messages | A | −37 | .12 | .003 | c' | -.05 | .09 | .55 |
| Perceived vaccine risk (Mediator) | – | – | – | b1 | -.27 | .11 | .014 | |
| Travel desire (Moderator) | – | – | – | b2 | .38 | .10 | <.001 | |
| Perceived vaccine risk x Travel desire | – | – | – | b3 | -.07 | .03 | .012 | |
| Constant | iM | 3.91 | .19 | <.001 | iY | .94 | .43 | .032 |
| Model 2: Message appeal (rational/emotional) R2 = .39, F(4,261) = 42.459, p < .001 | ||||||||
| Rational vs emotional message appeal | A | -.30 | .12 | .017 | c' | -.05 | .09 | .59 |
| Perceived vaccine risk | – | – | – | b1 | -.27 | .11 | .014 | |
| Travel desire | – | – | – | b2 | .37 | .10 | <.001 | |
| Perceived vaccine risk x Travel desire | – | – | – | b3 | -.07 | .03 | .013 | |
| Constant | iM | 3.81 | .20 | <.001 | iY | .93 | .44 | .034 |
| Model 3: Information about vaccine (obj/subj) x Message frame (gain/loss) R2 = .39, F(4,261) = 42.343, p < .001 | ||||||||
| Information type x Message frame | A | -.19 | .05 | <.001 | c' | -.00 | .04 | .99 |
| Perceived vaccine risk | – | – | – | b1 | -.27 | .11 | .015 | |
| Travel desire | – | – | – | b2 | .37 | .10 | <.001 | |
| Perceived vaccine risk x Travel desire | – | – | – | b3 | -.07 | .02 | .014 | |
| Constant | iM | 3.84 | .15 | <.001 | iY | .85 | .42 | .048 |
| Model 4: Information about vaccine (obj/subj) x Message appeal (ratio/emot) R2 = .39, F(4,261) = 42.344, p < .001 | ||||||||
| Information type x Message appeal | A | -.16 | .05 | .003 | c' | .00 | .04 | .96 |
| Perceived vaccine risk | – | – | – | b1 | -.27 | .11 | .015 | |
| Travel desire | – | – | – | b2 | .37 | .10 | <.001 | |
| Vaccine risk x Travel desire | – | – | – | b3 | -.07 | .03 | .013 | |
| Constant | iM | 3.77 | .15 | <.001 | iY | .84 | .43 | .04 |
Y: Outcome variable; M: Mediator; a: Effect of X on M; b1: Effect of M on Y; c': Direct effect of X on Y; b2: Effect of W on Y; b3: Moderated mediation effect of W on the relationship of M and Y. iM, iY = Coefficients for the constant.
| All COVID-19 vaccines currently available in the United States have been shown to be safe and highly effective at preventing COVID-19 virus. |
| All COVID-19 vaccines currently available in the United States have been shown to be safe and highly effective at preventing COVID-19 virus. |
| All COVID-19 vaccines currently available in the United States have been shown to be safe and highly effective at preventing COVID-19 virus. |
| All COVID-19 vaccines currently available in the United States have been shown to be safe and highly effective at preventing COVID-19 virus. |
| Based on evidence from clinical trials, COVID-19 vaccines that were approved in the United States are at least 86.7 percent effective against the COVID-19 virus. |
| Based on evidence from clinical trials, COVID-19 vaccines that were approved in the United States are at least 86.7 percent effective against the COVID-19 virus. |
| Based on evidence from clinical trials, COVID-19 vaccines that were approved in the United States are at least 86.7 percent effective against the COVID-19 virus. |
| Based on evidence from clinical trials, COVID-19 vaccines that were approved in the United States are at least 86.7 percent effective against the COVID-19 virus. |